Daily Endocrinology Research Analysis
Three impactful studies shape current endocrinology practice: a global consensus harmonizes MASLD/MASH management in the resmetirom era; a nationwide cohort quantifies elevated gallbladder/biliary risk with incretin drugs vs SGLT2 inhibitors irrespective of BMI; and a large ACCORD analysis links visit-to-visit lipid variability to incident heart failure in type 2 diabetes. Together, they refine screening, drug safety, and cardiometabolic risk stratification.
Summary
Three impactful studies shape current endocrinology practice: a global consensus harmonizes MASLD/MASH management in the resmetirom era; a nationwide cohort quantifies elevated gallbladder/biliary risk with incretin drugs vs SGLT2 inhibitors irrespective of BMI; and a large ACCORD analysis links visit-to-visit lipid variability to incident heart failure in type 2 diabetes. Together, they refine screening, drug safety, and cardiometabolic risk stratification.
Research Themes
- Consensus-driven care for MASLD/MASH in metabolic endocrinology
- Drug safety of incretin therapies versus SGLT2 inhibitors
- Visit-to-visit lipid variability as a predictor of heart failure in T2D
Selected Articles
1. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.
This Delphi-based global consensus harmonizes MASLD/MASH care across 61 recent guidelines, delivering highly agreed statements (>90% agreement) and practical algorithms spanning screening, fibrosis assessment, and therapy in the era of resmetirom. It emphasizes mandatory screening in T2D, noninvasive fibrosis stratification (e.g., FIB-4, VCTE), and surveillance in advanced fibrosis.
Impact: Provides unified, timely guidance for a highly prevalent metabolic liver disease tightly linked to T2D, likely to standardize care and inform policy and payer decisions worldwide.
Clinical Implications: Adopt routine MASLD screening in T2D, apply FIB-4 and VCTE-based pathways for fibrosis risk, consider resmetirom for appropriate MASH phenotypes, and implement HCC surveillance in advanced fibrosis/cirrhosis. Multidisciplinary metabolic care and weight loss interventions remain foundational.
Key Findings
- Comprehensive synthesis of 61 guidelines produced consensus statements with >90% agreement via four-round Delphi.
- Mandatory MASLD screening and noninvasive fibrosis assessment recommended in high-risk populations, notably T2D.
- Guidance updated for the resmetirom era, with algorithms for diagnosis, risk stratification, and surveillance.
Methodological Strengths
- Systematic, multi-database search and structured appraisal across eight domains and 145 variables.
- Formal Delphi process with predefined supermajority threshold ensuring high-consensus statements.
Limitations
- Consensus relies on underlying heterogeneous guideline evidence quality.
- Guideline recommendations may require regional adaptation and future updates as new trials report.
Future Directions: Prospective validation of algorithms in diverse health systems, integration with T2D care pathways, and real-world effectiveness of resmetirom-inclusive strategies.
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are associated with adverse clinical outcomes, impaired health-related quality of life, and significant economic burden. The growing burden of MASLD and MASH has led to the publication of a large number of MASLD/MASH guidelines by national and international societies. However, important differences among the recommendations have created confusion, contributing to a low implementation rate and suboptimal management of MASLD and MASH. Creating a consensus recommendation has become more important since the approval of a selective agonist of thyroid hormone β receptor (resmetirom) for MASH treatment in the United States. We built a consensus among the most recently published recommendations for MASLD/MASH. METHODS: A comprehensive search for MASLD and MASH guidelines, guidance documents, or similar publications from January 2018 to January 2025 using PubMed, Embase, Web of Science, and society websites was conducted. Each selected document was assessed across 8 specific domains with 145 variables. Variables with <50% concordance were used for the Delphi statement development. A supermajority threshold of 67% was set for statement acceptance. RESULTS: There were 61 documents published from 2018 through January 2025. Four rounds of Delphi were conducted: 46 statements were generated for Round 1, 32 statements for Round 2, 16 statements for Round 3, and 8 statements for Round 4, whereby 100% of statements achieved a greater than 90% agreement. All final consensus recommendations were summarized in tables and algorithms. CONCLUSIONS: Our study provides an extensive set of recommendations generated based on a comprehensive review of the most recent MASLD/MASH guidelines and a consensus-building process.
2. Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study.
In a nationwide, active-comparator, new-user design with large propensity score–matched cohorts, both DPP4 inhibitors and GLP-1 receptor agonists were associated with higher gallbladder/biliary disease risk than SGLT2 inhibitors, without BMI-based effect modification. Findings are consistent across obese, overweight, and normal-weight categories.
Impact: Directly informs drug selection in T2D by quantifying biliary risks of widely used incretin agents versus SGLT2 inhibitors across BMI strata.
Clinical Implications: In patients at higher baseline risk for gallbladder/biliary diseases, preferential consideration of SGLT2 inhibitors over incretin agents may reduce biliary events. Counsel patients on biliary symptoms and monitor accordingly irrespective of BMI.
Key Findings
- DPP4 inhibitors vs SGLT2 inhibitors: HR 1.21 (95% CI 1.14–1.28) for gallbladder/biliary disease.
- GLP-1 receptor agonists vs SGLT2 inhibitors: HR 1.27 (95% CI 1.07–1.50).
- No evidence of BMI-based effect modification (p=0.83 and p=0.73 for interaction).
Methodological Strengths
- Active-comparator, new-user design with very large 1:1 propensity score–matched cohorts.
- Consistent results across BMI strata and across two independent comparator cohorts.
Limitations
- Observational claims data subject to residual confounding and potential misclassification.
- Absolute risks and follow-up durations are not detailed in the abstract.
Future Directions: Head-to-head pragmatic trials or high-quality emulations assessing absolute risks, duration-response, and mechanisms of biliary effects with incretin therapies.
BACKGROUND: Despite emerging evidence of gallbladder or biliary tract diseases (GBD) risk regarding incretin-based drugs, population-specific safety profile considering obesity is lacking. We aimed to assess whether stratification by body mass index (BMI) modifies the measures of association between incretin-based drugs and the risk of GBD. METHODS: We conducted an active-comparator, new-user cohort study using a nationwide claims data (2013-2022) of Korea. We included type 2 diabetes (T2D) patients stratified by Asian BMI categories: Normal, 18.5 to <23 kg/m FINDINGS: New users of DPP4i and SGLT2i were 1:1 PS matched (n = 251,420 pairs; 186,697 obese, 39,974 overweight, and 24,749 normal weight pairs). The overall HR for the risk of GBD with DPP4i vs. SGLT2i was 1.21 (95% CI 1.14-1.28), with no effect modification by BMI (p-value: 0.83). For the second cohort, new users of GLP1RA and SGLT2i were 1:1 PS matched (n = 45,443 pairs; 28,011 obese, 8948 overweight, and 8484 normal weight pairs). The overall HR for the risk of GBD with GLP1RA vs. SGLT2i was 1.27 (1.07-1.50), with no effect modification by BMI (p-value: 0.73). INTERPRETATION: The increased risks of GBD were presented in both cohorts with no evidence of effect heterogeneity by BMI. FUNDING: Ministry of Food and Drug Safety, Health Fellowship Foundation.
3. Visit-to-Visit Variability in Lipid Levels and Risk of Incident Heart Failure in Adults With Type 2 Diabetes.
In ACCORD (n=9,443), higher visit-to-visit variability in TC, LDL-C, HDL-C, and TG independently predicted incident heart failure over 5 years, with adjusted HRs ranging 1.49–1.76 for highest vs lowest variability quartiles. Associations were consistent across variability metrics.
Impact: Highlights lipid variability as a modifiable risk dimension beyond mean levels for HF prevention in T2D, potentially informing targets for medication adherence and therapeutic smoothing.
Clinical Implications: Prioritize strategies that stabilize lipid levels (e.g., adherence optimization, long-acting statins/ezetimibe/PCSK9i), monitor variability in addition to means, and integrate HF risk stratification in T2D with lipid variability metrics.
Key Findings
- Across 9,443 T2D participants, 345 incident HF events occurred over 5.0 years.
- Highest quartile of lipid variability associated with higher HF risk: TC CV aHR 1.68; LDL-C CV aHR 1.76; HDL-C CV aHR 1.53; TG CV aHR 1.49.
- Findings were consistent using multiple variability metrics (CV, SD, variability independent of the mean).
Methodological Strengths
- Prospective repeated lipid measures at six time points enabling robust variability assessment.
- Adjusted Cox models in a large, well-characterized ACCORD cohort.
Limitations
- Observational analysis within a trial cohort; causality cannot be established.
- Generalizability may be limited to ACCORD-like populations.
Future Directions: Interventions targeting lipid variability (e.g., adherence programs, pharmacologic smoothing) should be tested for HF prevention in T2D.
OBJECTIVE: Limited data exist on the relation between long-term variability in blood lipid fractions and incident heart failure (HF) in the setting of type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: Among 9,443 participants with T2DM from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, with lipid measurements available at six time points (baseline, 4, 8, 12, 24, and 36 months), we assessed variability in total cholesterol (TC), LDL cholesterol, HDL cholesterol, and triglycerides (TG) across visits, using coefficient of variation (CV), SD, and variability independent of the mean. Cox proportional hazards models were employed to estimate adjusted hazard ratios (HRs) for incident HF. RESULTS: During a median follow-up of 5.0 years, 345 participants developed HF. Participants in the highest quartile of CV of TC had a 68% higher relative risk of HF compared with those in the lowest quartile (adjusted HR [aHR] 1.68, 95% CI 1.22-2.30). Similarly, those in the highest quartile of LDL cholesterol CV had a 76% higher relative risk (aHR 1.76, 95% CI 1.27-2.42) of HF, while those in the highest quartile of HDL cholesterol CV had a 53% higher risk (aHR 1.53, 95% CI 1.13-2.06). For TG CV, participants in the highest quartile had a 49% higher risk of HF compared with the lowest quartile (aHR 1.49, 95% CI 1.09-2.04). Similar patterns were observed for other variability metrics. CONCLUSIONS: Increased variability in TC, LDL cholesterol, HDL cholesterol, or TG is independently associated with a higher HF risk among individuals with T2DM.